$HIPH -Looking like its gearing up! Currently #undervalued

New Post Public Reply Private Reply Replies (0) Message Board
stockstein
284
$HIPH -Looking like its gearing up! Currently #undervalued in my opinion! News out a few days ago. See ThruEquity initiated coverage of $HIPH and put price target of $0.15. Some of you may recall See ThruEquity put a target on $POTN of $0.25 when it was $0.05. See below overview of research report & press release from See ThruEquity www.seethruequity.com/news


NEW YORK, NY / ACCESSWIRE / June 21, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage on American Premium Water Corp. (OTC PINK: HIPH) with a Target Price of $0.15.

The report is available here: June 2018 Initiation Report.

We initiate coverage on American Premium Water Corp. (OTC PINK: HIPH, $0.020) with a price target of $0.15. HIPH is a diversified company focused on premium consumer brands and products. It currently sells and markets hydrogen-infused water under the LALPINATM brand and luxury apparel under the Gents brand. We expect HIPH growth to be supported by two commercial initiatives planned for this year: Hydrogen-infused Water and Hydrogen CBD-infused Water. Both product lines have high potential given: 1) the rising consumer interest in legal CBD products; and 2) the large and expanding market for functional water. LALPINATM Hydrogen is already selling via select channels, and the company is planning for a full-scale launch in the coming quarters. The company debuted LALPINATM Hydrogen CBD in January 2018, and it is expected to be launched in June 2018. The functional bottled water market in the US is expected to reach ~$2.9 billion by 2020 driven by a shift in consumer preference from soda-based to more nutritional and healthier drinks. This is evident from the rising demand of seltzer water, ionized water and smart water, among others. Hydrogen-infused water has the potential to become a new category in this trend. HIPH has an early mover advantage in the hydrogen infused water market which currently has limited competition.

LALPINA Hydrogen CBD positions the company to tap into growing consumer interest around CBD related products as this is the only known Hydrogen CBD water in the market. There is a large market opportunity given the growing number of cannabis dispensaries which could be potential customers.

We are also intrigued by management's effort to position Gents as an emerging luxury apparel brand. The recent acquisition of Worthy, a JV with China-based Zhangjiagang Advanced Company (ZAC), and collaborations with Showtime and SoulCycle should help expand footprint and consumer reach. HIPH has also entered the fast growing blockchain space via the acquisition of FashionCoinX, which further diversifies its potential revenue streams. HIPH noted a number of acquisition opportunities in the pipeline - all of which could further support growth. Going forward, we expect HIPH to increase revenues and earnings via new product launches, aggressive distribution and marketing, entry into new regions and M&A.

Well positioned as a luxury consumer lifestyle brand

HIPH manufactures and distributes consumer products under the LALPINATM and Gents brands. The LALPINATM brand focuses on hydrogen infused bottled water via its two products: LALPINATM Hydrogen (launched in 1Q18) and LALPINATM Hydrogen CBD (to be launched in June 2018). The bottled water market with functional benefits such as added alkalinity, electrolytes, vitamins, minerals is seeing significant traction among consumers. The shift in consumer preference to healthier and nutritional drinks is likely to further drive the growth of functional water market. The functional bottled water market in the US is expected to reach ~$2.9 billion by 2020. HIPH has an early mover advantage in the hydrogen infused water market which currently has limited competition. LALPINATM Hydrogen CBD is a front runner in the space as the only known hydrogen infused CBD beverage available on the market. The primary competitive advantage is that it improves bioavailability of CBD and absorption. The CBD market could reach $2.1 billion by 2020, according to Hemp Business Journal.

Gents is a producer of luxury hats and other fine accessories and apparel. Presence in 200 retail outlets internationally including upscale names such as Bloomingdale's, Nordstrom, and Saks Fifth Avenue strengthens its positions as a luxury brand. The acquisition of New York-based streetwear brand, Worthy further diversifies the apparel revenue stream. It will expand the price points offered by Gents and opens up many new distribution channels.

Expansion in blockchain/crypto space

The recent acquisition of FashionCoinX marks HIPH's entry in the fast growing blockchain/crypto space. Blockchain is one of the fastest growing technologies and entry in the space should benefit HIPH. According to Market Reports Center, the size of the blockchain industry will grow to $60.7 billion by the year 2024. HIPH is looking for more opportunities in the blockchain/crypto space that will complement its existing LALPINATM and Gents brands.

Aggressive marketing push to drive topline

HIPH plans to enter into partnerships and collaborations to increase distribution and marketing reach. The JV with China-based Zhangjiagang Advanced Company and collaborations with Showtime drama 'Billions' and fitness chain SoulCycle should help expand Gents footprint and consumer reach. Further, LALPINA's distribution agreement with GNC, one of the world's largest vendors of health and nutritional products, is likely to result in strong order flow. The management noted that it is working on several more distribution partnerships for both brands which should further bolster the topline.

Initiate coverage with a price target of $0.15

We see HIPH as a high risk and high reward consumer brand play. The target of $0.15 assumes that the company is successful in executing its organic and inorganic growth revolving around product expansion, strategic partnerships and M&A. Key risks include inability to raise capital for its growth initiatives and delay in the launch of LALPINATM Hydrogen CBD.

Please review important disclosures in the report and on our website at www.seethruequity.com.

About American Premium Water Corp.

HIPH is a manufacturer, distributor, and marketer of branded consumer products. It currently markets and distributes products under LALPINATM and Gents brands. Under the LALPINATM brand, the company develops hydrogen-infused energy products. Currently, the product line includes - 1) LALPINATM Hydrogen and 2) LALPINATM Hydrogen CBD. Gents is a producer of luxury hats and other fine accessories and apparel. The brand is carried in over 200 retail outlets internationally, including Bloomingdale's, Nordstrom, and Saks Fifth Avenue, among other boutiques and upscale retailers. For more information, visit www.americanpremiumwater.com

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative approach to deliver equity research of microcap and smallcap companies. SeeThruEquity has also been the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion since 2012.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry's most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 3

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Clover's RSV Combo Vaccine Shows Promise in Trials

Updated Category News Views 1

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 12

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
ATTACK SHARK Partners with Cloud9 League Team

Updated Category News Views 2

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Continue Reading
Zendure, SolarFlow Pro Win Big at IFA 2026 Tech Awards

Updated Category News Views 2

Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...

Continue Reading
Media Forum Spotlights Asia-Pacific Cooperation

Updated Category News Views 3

The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...

Continue Reading
Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 0

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading

Top 5 Most Recently Viewed Articles

Prologis Earnings Report: Investors' Key Insights and Analysis

Updated Category News Views 138

Understanding Prologis's Upcoming Quarterly Earnings Prologis (NYSE: PLD) is set to release its latest quarterly earnings report, and investors are eagerly awaiting the insights it will provide. As the company approaches its earnings announcement, analysts project an earnings per share (EPS) of $1.02, which serves as a benchmark for performance expectations. Investor...

Continue Reading
How Changing U.S. Jobs Report Affects Market Dynamics

Updated Category News Views 171

The recent U. S. employment report sent shockwaves through financial markets, reshaping how traders and investors eyed their portfolios. Stronger-than-expected job creation—with figures soaring over 100,000—meant one thing: the narrative on interest rates was about to change. Gone were the days of comfortably betting on rate cuts; now, everyone’s scrambling to...

Continue Reading
Suno Boosts Innovation for Creators by Acquiring WavTool

Updated Category News Views 157

Suno Boosts Innovation for Creators by Acquiring WavTool Suno has recently made a significant move in the music industry with their acquisition of WavTool. This strategic decision aims to enhance their offerings for songwriters and producers, enabling them to create music that resonates with a broader audience. By integrating WavTool's advanced capabilities into their...

Continue Reading
Leqembi's New IV Treatment Approval: A Milestone for Alzheimer’s Care

Updated Category News Views 274

Leqembi Approved for IV Maintenance Treatment BioArctic AB, a notable player in the biopharmaceutical sector, has made significant headlines with the approval of Leqembi (lecanemab) for intravenous (IV) maintenance treatment for Alzheimer’s disease in the United Kingdom. This groundbreaking decision was announced following rigorous evaluations by the Medicines and...

Continue Reading
Investors of ATYR, MLTX, BAX, and JHX Have Legal Options

Updated Category News Views 145

Overview of Class Action Lawsuits for ATYR, MLTX, BAX, JHX Attention investors! If you’ve invested in aTyr Pharma Inc. (NASDAQ: ATYR), MoonLake Immunotherapeutics (NASDAQ: MLTX), Baxter International, Inc. (NYSE: BAX), or James Hardie Industries plc (NYSE: JHX), it’s important to be aware of significant class action lawsuits affecting your investments. These companies...

Continue Reading